Kangfang Biotech announced that the first global phase III clinical trial of cardonilizumab compared with navulimab for first-line treatment of gastric cancer has completed the enrollment of the first patient.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.